Agios Pharmaceuticals Inc

Financials

Activos totales 852.95 M1.44 B1.24 B937.12 M1.66 B1.3 B Total de pasivos 453.45 M145.76 M137.9 M126.1 M122.24 M104.11 M Capital total 399.5 M1.29 B1.1 B811.02 M1.54 B1.19 B Total de pasivos y patrimonio neto 852.95 M1.44 B1.24 B937.12 M1.66 B1.3 B Deuda total —————— Deuda neta ——————

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

AGIO

Financials

Agios Pharmaceuticals Inc

Noticias

AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD

Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?

Leerink reitera calificación de acciones de Fulcrum Therapeutics por flexibilidad de la FDA

BofA eleva el precio objetivo de Agios Pharma por su vía regulatoria en ECF

Stifel ve infravaloradas las acciones de Fulcrum por flexibilidad de la FDA

Agios Rallies On A Surprise FDA Move In Sickle Cell, Pulling Rival Fulcrum Higher

Truist reitera calificación de acciones de Agios Pharma por vía de aprobación acelerada

Las acciones de Agios se disparan tras la vía de la FDA para la aprobación de mitapivat

Agios buscará aprobación acelerada para mitapivat en células falciformes

Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why

Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss

Truist Securities eleva el precio objetivo de Agios Pharma a 39 dólares por el progreso de su cartera